U.S. markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5604-0.0028 (-0.50%)
At close: 04:00PM EDT
0.5419 -0.02 (-3.30%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.5632
Bid0.5414 x 2900
Ask0.5578 x 1100
Day's Range0.5420 - 0.5800
52 Week Range0.2410 - 1.2000
Avg. Volume2,213,919
Market Cap104.234M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.4700
Earnings DateMay 08, 2023 - May 12, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AKBA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Akebia Therapeutics, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • PR Newswire

    Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company met with the U.S. Food and Drug Administration (FDA) Office of New Drugs (OND) deciding authority to discuss Akebia's Formal Dispute Resolution regarding the Complete Response Letter for vadadustat received in March 2022.

  • PR Newswire

    Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting

    Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders scheduled on April 11, 2023 at 10:00 a.m. ET in a virtual meeting format as a live webcast. Akebia is holding the Special Meeting to seek stockholder approval to, among

  • Insider Monkey

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia’s Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please […]